Navigation Links
Helix BioPharma Announces Q3 2009 Financial Results and Provides Product Development Update
Date:6/15/2009

ilable on EDGAR at www.sec.gov/edgar.shtml .

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate and Topical Interferon Alpha-2b. Helix is listed on the TSX under the symbol "HBP".


    For further information contact:

    Investor & Media Relations
    Ian Stone
    Russo Partners LLC
    Tel: (619) 814-3510
    Fax: (619) 955-5318
    Email: ian.stone@russopartnersllc.com

    Robert Flamm, Ph.D.
    Russo Partners LLC
    Tel: (212) 845-4226
    Email: robert.flamm@russopartnersllc.com

    www.russopartnersllc.com

Reported financial information may not necessarily be indicative of future operating results or of future financial position, due to a number of risks and uncertainties, including those set forth below. This News Release contains certain forward-looking statements and information regarding the Company's activities and finances, including the future timing thereof, which statements and information can be identified by the use of forward-looking terminology such as "future", "in anticipation", "to produce", "to be used", "forward", "plans", "to seek", "to initiate", "expected", "believe", "next", "ongoing", "continue", "estimated", "October 31, 2009", "2010" "within approximately six months" or the negative thereof or any other variations thereon, or that events or conditions "will", "may" or "could", "would", or "should" occur or be achieved, or comparable terminology referring to future events or results.
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. Helix BioPharma closes $16.9 million private placement of common shares
8. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
9. Helix BioPharma shareholders vote in favour of management
10. Helix BioPharma reports Q2 2008 highlights, financial results
11. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... “Our nation's healthcare system is broken, ... Furthermore, every governmental and professional entity that has ... of unorganized dysfunction shares in that enormous blame. ... as a device to use in an effort ... have accumulated through the years leading to the ...
(Date:8/21/2014)... for Molecular Medicine Finland (FIMM), University of Helsinki, ... "man and machine" decision support system for diagnosing ... in PLOS One scientific journal today, ... vision algorithms similar to those used in facial ... diagnostically most relevant areas. Tablet computers can be ...
(Date:8/21/2014)... DUBLIN, Ireland , August 21, 2014 ... and Markets ( http://www.researchandmarkets.com/research/3zh3q8/global_hormone ) has announced the ... Market 2014-2018"  report to their offering.  ... also known as hormone therapy, is a ... longer being produced by the body. This ...
(Date:8/21/2014)... August 21, 2014 The College of ... private college in the Mid-Hudson Region to be designated ... begin accepting applications from qualified “high-technology” businesses that align ... very pleased to have been selected for the START-UP ... transformative initiative to stimulate economic development in New York ...
Breaking Biology Technology:5 Great Mistakes in Healthcare and How to Fix Them by Dr. Ira Williams 2A novel 'man and machine' decision support system makes malaria diagnostics more effective 2Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 3
... ... ... 2009 -- As part of ongoing efforts to expand deployment of 21st century environmental ... soil , sediment and groundwater remediation industry, is pleased to announce formal ...
... SEATTLE, Dec. 8 Dendreon Corporation (Nasdaq: DNDN ) ... subject to market and other conditions, of 15,000,000 shares of ... Dendreon intends to grant to the underwriters a ... of common stock to cover over-allotments, if any. J. ...
... OMAHA, Neb., Dec. 8 Transgenomic, Inc. (OTC Bulletin Board: ... kit, the first in a family of mutation detection kits ... and WAVE ® HS DHPLC platform. SURVEYOR Scan ... a PCR amplification reaction and hybridization to form heteroduplex DNA ...
Cached Biology Technology:Olympics 2016, World Cup 2014, But First – Adventus Brasil 2009 2Olympics 2016, World Cup 2014, But First – Adventus Brasil 2009 3Olympics 2016, World Cup 2014, But First – Adventus Brasil 2009 4Dendreon Announces Proposed Public Offering of Common Stock 2Dendreon Announces Proposed Public Offering of Common Stock 3Transgenomic Announces the Commercial Launch of SURVEYOR(R) Scan K-RAS Mutation Detection Kit 2Transgenomic Announces the Commercial Launch of SURVEYOR(R) Scan K-RAS Mutation Detection Kit 3Transgenomic Announces the Commercial Launch of SURVEYOR(R) Scan K-RAS Mutation Detection Kit 4
(Date:8/21/2014)... A team of researchers at Louisiana ... for using affordable, consumer-grade 3D printers and ... can contain antibacterial and chemotherapeutic compounds for ... of doctoral students and research faculty from ... programs collaborated to create filament extruders that ...
(Date:8/20/2014)... 158 pregnant teenagers in Rochester, NY, nearly half engaged ... ice, cornstarch, vacuum dust, baby powder and soap, and ... Moreover, such teens had significantly lower iron levels as ... , Pregnant teens, regardless of pica, are at higher ... deficiency and anemia. Low iron in pregnant teens raises ...
(Date:8/20/2014)... in in this image of the Para and Mato ... most likely intentionally set in order to deforest the ... stand of trees where the land is thereafter converted ... of forestland to farms, ranches, or urban use. The ... the Amazon Rainforest in the middle of the image ...
Breaking Biology News(10 mins):Louisiana Tech University researchers use 3D printers to create custom medical implants 2Louisiana Tech University researchers use 3D printers to create custom medical implants 3Pica in pregnant teens linked to low iron 2
... Changes to proteins in a cell underlay many cancers. ... in Portugal, in collaboration with researchers in Ghent (Belgium) ... understand exactly how changes to proteins, identified in the ... living organism. This study, funded by the Association for ...
... In prehistoric times farmers across the world domesticated ... result the ancestral plants have been lost, causing problems ... but that might change. A team led by Fabiola ... has managed to trace a domesticated cactus, the Gray ...
... (August 23, 2010) A clue to the causes ... the tiny intercellular junction that rapidly transfers information from ... Tufts University School of Medicine, with students from the ... protein called APC (adenomatous polyposis coli) plays a key ...
Cached Biology News:Understanding cancer using the fruit fly 2Cactus genes connect modern Mexico to its prehistoric past 2Researchers connect APC protein to autism and mental retardation 2
... cocktail of 3 siRNAs specifically targeted to ... popular product. The siTrio reagent guarantees you ... target gene when used under standard conditions ... of optimal transfection with one of B-Bridges ...
... cocktail of 3 siRNAs specifically targeted to ... popular product. The siTrio reagent guarantees you ... target gene when used under standard conditions ... of optimal transfection with one of B-Bridges ...
... siTrio siRNA --- a cocktail of 3 ... of interestis our most popular product. The ... 75% knockdown of your target gene when ... for transfection and confirmation of optimal transfection ...
... is a competitive enzymeimmunoassay (EIA) for the ... rat serum or plasma. Corticosterone is the ... and mice, and in most non-mammalian vertebrates ... mammals produce both corticosterone and cortisol, in ...
Biology Products: